300171 Tofflon Science and Technology GroupWatchlist
Tofflon Science and Technology Group News
Dongfulong (300171): Under the influence of macro factors, the profit side is under pressure, and the fund-raising project is progressing smoothly
Dongfulong (300171): Actively developing customers and looking forward to order resumption
Dongfulong (300171): Revenue side growth is steady, pharmaceutical division and food division have impressive growth rates
Dongfulong (300171): Performance is growing steadily, and there is broad scope for domestic replacement of pharmaceutical equipment
Dongfulong (300171) 2023 Interim Report Review: Injections Drive Steady Performance Growth and Continued Market Share Expansion
Tofulon (300171): Steady revenue growth in the first half of 2023
Dongfulong (300171): Revenue side growth, steady gross margin fluctuations affect profit performance
Dongfulong (300171) 2023H1 review: The injectables business drove rapid growth in performance in the first half of the year
Dongfulong (300171): Revenue continues to grow steadily
Dongfulong (300171): Revenue for the single third quarter increased by 29.6% year on year and continued to promote internationalization & diversified layout
East Fulong (300171): Q3 order delivery rhythm starts a new round of capacity expansion
East Fulong (300171): revenue-side growth is in line with expectations, short-term gross profit margin decline causes profit side pressure
East Fulong (300171): pharmaceutical equipment leader to create the second growth curve of consumables, CGT, etc.
Dongfulong (300171) In-depth Report: Jiaolong's full-industry integration strategy breaks the cycle by going overseas
Dong Fulong (300171): the potential of capacity optimization and release due to the slowdown of epidemic disturbance growth.
Dong Fulong (300171): the disturbance of the epidemic situation does not change the expectation of continuous development of overseas business throughout the year.
East Fulong (300171): the company's overall performance is under pressure due to the impact of the steady epidemic situation in the second quarter.
East Fulong (300171): the performance is in line with the expected overseas growth in the context of the epidemic, which is expected to open up room for long-term growth.
Brief Review report of East Fulong (300171) Company: the performance is in line with expectations and the company's operation is expected to improve gradually in the second half of the year.
East Fulong (300171) semi-annual report comments: short-term epidemic impact does not change the company's long-term development prospects